

Sandra P D'angelo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4184683/publications.pdf>

Version: 2024-02-01

73
papers

12,787
citations

172457

29
h-index

128289

60
g-index

74
all docs

74
docs citations

74
times ranked

17768
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
2	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 375-384.	10.7	2,353
3	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1374-1385.	10.7	1,034
4	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015, 33, 3193-3198.	1.6	892
5	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncology</i> , The, 2018, 19, 416-426.	10.7	517
6	Molecular Epidemiology of <i>EGFR</i> and <i>KRAS</i> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <i>KRAS</i> -Mutant Cancers. <i>Clinical Cancer Research</i> , 2012, 18, 6169-6177.	7.0	503
7	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	1.6	458
8	Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced <i>CDK4</i> -Amplified Well-Differentiated or Dedifferentiated Liposarcoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2024-2028.	1.6	370
9	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. <i>Cancer Discovery</i> , 2018, 8, 944-957.	9.4	313
10	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e180077.	7.1	304
11	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
12	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. <i>Human Pathology</i> , 2015, 46, 357-365.	2.0	252
13	Incidence of <i>EGFR</i> Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2011, 29, 2066-2070.	1.6	247
14	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016, 4, 383-389.	3.4	247
15	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With <i>CDK4</i> Inhibitor Palbociclib. <i>JAMA Oncology</i> , 2016, 2, 937.	7.1	241
16	Distinct Clinical Course of <i>EGFR</i> -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1815-1822.	1.1	160
17	Ipilimumab for Patients With Advanced Mucosal Melanoma. <i>Oncologist</i> , 2013, 18, 726-732.	3.7	140
18	Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3166-3174.	1.6	133

#	ARTICLE	IF	CITATIONS
19	Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. , 2020, 8, e000674.		132
20	Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma. American Journal of Surgical Pathology, 2014, 38, 1118-1127.	3.7	131
21	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. JAMA Oncology, 2020, 6, 402.	7.1	125
22	Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations. Journal of Thoracic Oncology, 2011, 6, 569-575.	1.1	124
23	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research, 2017, 23, 2972-2980.	7.0	106
24	Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. , 2019, 7, 276.		101
25	Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 319-330.e1.	0.8	96
26	Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation. Clinical Lung Cancer, 2014, 15, 405-410.	2.6	63
27	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	12.8	63
28	Cytokine release syndrome after radiation therapy: case report and review of the literature. , 2018, 6, 1.		54
29	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq1 1 0.784314 rgBT /Overl		32
30	Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 476-480.	0.8	40
31	Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. Oncology, 2015, 89, 205-214.	1.9	38
32	Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial. OncoImmunology, 2018, 7, e1372081.	4.6	37
33	A phase Ib study of BCGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational New Drugs, 2019, 37, 282-290.	2.6	32
34	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARCO28 and biomarker analyses.. Journal of Clinical Oncology, 2017, 35, 11008-11008.	1.6	32
35	Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?. Annals of Thoracic Surgery, 2017, 104, 1837-1845.	1.3	28
36	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.. Journal of Clinical Oncology, 2017, 35, 11001-11001.	1.6	26

#	ARTICLE	IF	CITATIONS
37	A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401).. Journal of Clinical Oncology, 2017, 35, 11007-11007.	1.6	26
38	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. Oncologist, 2015, 20, 1245-1246.	3.7	25
39	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 609-618.	4.2	21
40	Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nature Communications, 2022, 13, .	12.8	21
41	Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1^{c259}t in HLA-A2⁺ patients with synovial sarcoma (NCT01343043).. Journal of Clinical Oncology, 2017, 35, 3000-3000.	1.6	20
42	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
43	A Case Series of Dose-Limiting Peripheral Edema Observed in Patients Treated with Pemetrexed. Journal of Thoracic Oncology, 2011, 6, 624-626.	1.1	18
44	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precision Oncology, 2020, 4, 1350-1360.	3.0	18
45	Percutaneous Cryoablation Provides Disease Control for Extra-Abdominal Desmoid-Type Fibromatosis Comparable with Surgical Resection. Annals of Surgical Oncology, 2022, 29, 640-648.	1.5	17
46	Efficacy and immune-related adverse event associations in avelumab-treated patients. , 2020, 8, e001427.		16
47	A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2015, 33, 10507-10507.	1.6	16
48	Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. , 2022, 10, e003302.		16
49	Current status of engineered T-cell therapy for synovial sarcoma. Immunotherapy, 2016, 8, 1073-1080.	2.0	15
50	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2022, 40, 997-1008.	1.6	13
51	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. Clinical Cancer Research, 2020, 26, 5448-5455.	7.0	12
52	Patient Experiences with Avelumab in Treatment-Naive Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. Patient, 2020, 13, 457-467.	2.7	11
53	18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.. Journal of Clinical Oncology, 2018, 36, 192-192.	1.6	11
54	The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 834-844.	4.9	11

#	ARTICLE	IF	CITATIONS
55	First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.. Journal of Clinical Oncology, 2017, 35, 9530-9530.	1.6	10
56	Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. Clinical Cancer Research, 2022, 28, 939-947.	7.0	10
57	The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation-associated angiosarcomas of the breast. Histopathology, 2021, 79, 836-846.	2.9	9
58	Immunotherapy in Sarcoma. Surgical Oncology Clinics of North America, 2022, 31, 381-397.	1.5	9
59	Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e558-e564.	3.8	8
60	Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases. Frontiers in Oncology, 2021, 11, 725484.	2.8	4
61	Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor. Oncologist, 2021, 26, e710-e714.	3.7	3
62	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2017, 35, 11010-11010.	1.6	3
63	Association between objective responses (OR) and overall survival (OS) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab.. Journal of Clinical Oncology, 2018, 36, 193-193.	1.6	3
64	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2022, 28, 1507-1517.	7.0	3
65	Health-related quality of life trajectory of treatment-naïve patients with Merkel cell carcinoma receiving avelumab. Future Oncology, 2020, 16, 2089-2099.	2.4	2
66	Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients. Sarcoma, 2020, 2020, 1-8.	1.3	2
67	Abstract 4707: Genetically engineered NY-ESO-1-specific T cells in HLA-A2+ patients with synovial sarcoma. , 2015, , .		2
68	A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).. Journal of Clinical Oncology, 2017, 35, TPS3097-TPS3097.	1.6	1
69	Risk factors associated with ifosfamide (IFOS)-induced encephalopathy in patients (pts) with metastatic (Met) sarcoma (Sarc).. Journal of Clinical Oncology, 2017, 35, e22518-e22518.	1.6	1
70	Reply to A. Indini et al. Journal of Clinical Oncology, 2016, 34, 1018-1019.	1.6	0
71	Immune Checkpoint Inhibitors in Sarcoma. , 2019, , 125-137.		0
72	A phase Ib study of BGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2017, 35, 11039-11039.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Maximizing Immunotherapy in Sarcoma Using Histology, Biomarkers and Novel Approaches. Touch Reviews in Oncology & Haematology, 2022, 18, 73.	0.2	0